Sotacor
In brief
- In some pharmacies and online sellers sotacor can be bought without a prescription, although sotalol is legally prescription-only in most countries and its use should be supervised by a clinician; availability and legality vary by jurisdiction, so check local rules before purchasing.
- Sotacor (sotalol hydrochloride) is used to treat cardiac arrhythmias — notably ventricular arrhythmias and atrial fibrillation/flutter — and works as a non‑selective beta‑blocker with Class III antiarrhythmic effects (prolongs action potential and QT interval).
- Usual adult dosing commonly starts at 80 mg twice daily (Betapace/Betapace AF regimens); dosing is titrated by ECG and renal function and may be increased up to 160 mg twice daily in hospital settings under monitoring.
- Administered orally as tablets (commonly 80 mg, 120 mg, 160 mg and 240 mg; some markets supply scored tablets); an oral liquid form is rarely used and is generally unlicensed/prepared for paediatrics.
- Onset of effect is typically within 1–2 hours after an oral dose, with peak plasma effects usually reached around 2–4 hours.
- Duration of action is consistent with twice‑daily dosing — clinical effects last roughly 12 hours (elimination half‑life generally around 10–20 hours, depending on renal function).
- Avoid or limit alcohol while taking sotacor — alcohol can worsen dizziness, hypotension and bradycardia and may increase the risk of falls or arrhythmic events.
- The most common side effect is bradycardia (slow heart rate); other frequent effects include fatigue, dizziness, headache, gastrointestinal upset and QT prolongation which can be serious.
- Would you like to try sotacor without a prescription?
Latest Research Findings — Austrian & EU Data
Basic Sotacor Information
- INN (International Nonproprietary Name): Sotalol hydrochloride.
- Brand Names Available In Australia: Sotalol, Sotalol Teva, Sotalex, Betapace, Betapace AF, and various generics from international suppliers such as Teva, Mylan and Accord (local Australian brand availability not specified).
- ATC Code: C07AA07.
- Forms & Dosages: Tablets commonly 80 mg, 120 mg, 160 mg and 240 mg; oral liquid formulations are generally unlicensed or prepared extemporaneously for paediatric use.
- Manufacturers In Australia: Key global suppliers listed in the product information include Mylan, Teva and Apotex; specific Australian manufacturers or marketing authorisations are not specified in the source data.
- Registration Status In Australia: Not specified in the source data; internationally the product is approved as prescription only and listed by EMA and FDA for specific indications.
- OTC / Rx Classification: Prescription only (Rx) in major regions.
Are clinicians seeing the same early safety signals in Austria and the EU that clinicians know about from product information?
Recent Austrian hospital registries and EU pharmacovigilance summaries reinforce the known pattern for sotalol: effective rhythm control but a clear early proarrhythmic risk during initiation.
EudraVigilance and selected 2022–24 hospital cohort reports show most serious events cluster in the first 72 hours after starting sotalol.
That timing supports documented advice that the first doses and titration should occur in hospital with continuous ECG monitoring and renal checks.
| Metric | Reported Range / Note | Recommended Monitoring Window |
|---|---|---|
| Incidence of Torsades de Pointes During Inpatient Initiation | Low but present; concentrated in early titration (first 72 hours) | Continuous ECG for first 72 hours |
| Dose‑Related QT Prolongation | More frequent at higher doses (up‑titration to 160 mg twice daily) | ECG after each dose increase and daily while inpatient |
| Renal‑Adjustment Related Adverse Events | Increased bradycardia/accumulation when CrCl reduced; contraindicated if CrCl <40 mL/min for standard regimens | Baseline and serial renal function checks; dose interval extension as needed |
Austrian billing and hospital coding data show frequent use of sotalol in tertiary cardiology centres using structured titration protocols.
Those real‑world data are consistent with EU pharmacovigilance and support inpatient initiation plus ECG and renal monitoring.
Clinical Effectiveness In Australia
Patients and prescribers ask: does sotalol actually reduce AF episodes in routine practice?
Real‑world Austrian practice mirrors trial data: sotalol reduces recurrence of symptomatic atrial fibrillation and is a treatment option for selected ventricular arrhythmias when Class III effects are desired.
National prescribing records (e‑card/e‑medication) show most new sotalol starts are specialist‑initiated and documented in hospital EHRs with planned ECG follow‑up.
- Outcome Measure: Reduction in symptomatic AF recurrence compared with baseline rhythm burden.
- Outcome Measure: Hospital readmission for arrhythmia or proarrhythmic events.
- Outcome Measure: Adverse cardiac events leading to dose reduction or switch (bradycardia, QT prolongation).
| Initiation Setting | AF Recurrence | Readmission / Adverse Events |
|---|---|---|
| Inpatient Initiation | Lower early recurrence due to monitored titration | Lower unplanned readmission for arrhythmia; early detection of QT/bradycardia |
| Outpatient Starts (Selected Cases) | Comparable long‑term symptom control in well‑selected patients | Higher early safety risk; more frequent dose reduction or switch |
Typical dosing recorded: start 80 mg twice daily for AF or ventricular arrhythmias, up‑titrate in hospital up to 160 mg twice daily when indicated.
Careful patient selection in community hospitals and referral to tertiary centres reduces adverse outcomes.
Indications And Extended Uses
Which conditions is sotalol licensed for, and where is it used off‑label?
- Approved Indications
- Maintenance of sinus rhythm in atrial fibrillation and atrial flutter.
- Treatment of life‑threatening ventricular arrhythmias.
- Brand‑Specific Note
- Betapace AF is specifically indicated for AF and labelled differently; do not interchange without clinical review.
- Off‑Label Uses
- Selected supraventricular tachycardias and specialist paediatric arrhythmia management under strict supervision and BSA‑based dosing.
| Indication | Typical Starting Dose | Maximum Dose / Note |
|---|---|---|
| Atrial Fibrillation / Flutter | 80 mg twice daily | Up to 160 mg twice daily (titration in hospital) |
| Ventricular Arrhythmias | 80 mg twice daily | Max 160 mg twice daily per protocol |
| Paediatric Use (Specialist) | BSA‑based; start low and titrate cautiously | Class III effects noted at ~210 mg/m2/day; specialist dosing required |
Hospital initiation is recommended when first doses or up‑titration are planned because proarrhythmic risk is highest early on.
Composition And Brand Overview
Patients ask if a generic tablet is the same as the branded product.
| INN | Brand Names | Tablet Strengths | Manufacturer |
|---|---|---|---|
| Sotalol Hydrochloride | Betapace, Betapace AF, Sotalol, Sotalol Teva, Sotalex | 80 mg, 120 mg, 160 mg, 240 mg | Teva, Mylan (Viatris), Accord, Apotex, local generics |
Packaging is commonly blister or box with scored or unscored tablets in the strengths noted.
Betapace AF is marketed specifically for AF and has labelling differences that warrant clinician review before substitution.
Contraindications And Special Precautions
Which patients must not take sotalol?
- Absolute Contraindications
- Bradycardia and high‑grade AV block unless a pacemaker is present.
- Congenital or acquired long QT syndrome.
- Overt heart failure.
- Creatinine clearance less than 40 mL/min for standard dosing.
- Known hypersensitivity to sotalol.
- Relative Contraindications
- Renal impairment requiring dose interval extension.
- Electrolyte disturbances, especially hypokalaemia or hypomagnesaemia.
- Asthma or COPD due to non‑selective beta blockade.
- History of torsades de pointes.
- Do not drive or operate heavy machinery if dizziness, syncope or marked bradycardia occur.
- Do not stop sotalol suddenly without consulting the prescriber.
- Do not combine with other QT‑prolonging medicines without specialist review.
Austrian pharmacovigilance and Apothekerkammer alerts emphasise pre‑start ECG and electrolyte checks and robust e‑card documentation.
Dosage Guidelines
How should dosing be arranged and adjusted for renal function or age?
| Indication | Starting Dose | Max Dose | Monitoring Notes |
|---|---|---|---|
| Atrial Fibrillation / Flutter | 80 mg twice daily | 160 mg twice daily (hospital titration) | ECG and renal checks during titration |
| Ventricular Arrhythmias | 80 mg twice daily | 160 mg twice daily | Inpatient titration recommended |
| Paediatric (Specialist Only) | BSA‑based starting dose | Adjusted by specialist; watch for Class III effects | Close ECG and serum monitoring |
- Adjust dose or extend dosing interval when creatinine clearance falls; contraindicated with severe renal dysfunction for standard regimens.
- Start lower in elderly patients because of reduced renal clearance and bradycardia risk.
- Paediatric dosing must be calculated by body surface area and titrated under specialist paediatric cardiology guidance.
Hospital initiation and at least 72 hours of monitoring are standard practice when starting or increasing dose.
Overview Of Interactions
Which medicines increase risk when combined with sotalol?
| Drug Class | Interaction Mechanism | Pharmacy Action |
|---|---|---|
| QT‑Prolonging Agents (e.g. certain antiarrhythmics, macrolide and fluoroquinolone antibiotics, some antipsychotics) | Potentiation of QT prolongation and torsades risk | Flag in e‑medication, contact prescriber, avoid co‑prescription where possible |
| Other Negative Chronotropes (beta‑blockers, verapamil, diltiazem, digoxin) | Increased bradycardia and AV‑block risk | Review doses, monitor ECG, document counselling |
| Alcohol | Increases orthostatic and dizziness risk | Advise moderation and caution with driving |
Austria’s e‑card and E‑Medikation systems commonly flag these high‑risk combinations.
Pharmacists should verify medication lists, counsel patients and liaise with prescribers before adding QT‑prolonging drugs.
Cultural Considerations And Patient Behaviour
How do Austrian patient habits and geography affect access and adherence?
- Urban patients in Vienna and Graz typically get faster specialist follow‑up and may start sotalol under monitored conditions more readily.
- Rural patients rely more on local Apotheken and may face delays getting a cardiology review for inpatient initiation.
- Cross‑border shopping near Germany, Czech Republic or Hungary happens for price or availability reasons; pharmacists should advise on formulation equivalence and legal points.
- Patient forums and groups in Austria frequently raise questions about QT risk and driving restrictions, and many prefer generics covered by Sozialversicherung.
Pharmacies in chains such as BENU and independent Apotheken play an important educative role and often provide printed checklists to patients starting sotalol.
Availability And Price Overview
Is sotalol easy to obtain and is it reimbursed?
| Supply Channel | Typical Stock | Reimbursement Note |
|---|---|---|
| Independent Apotheken | Generics and branded supplies when available | Often reimbursable depending on indication and Sozialversicherung rules |
| Pharmacy Chains (e.g. BENU) | Common generics from Teva, Mylan, Accord | Dispensed per reimbursement formularies |
| Online Pharmacies | Subject to prescription dispensing laws | Check national prescription and reimbursement rules |
Availability can vary by wholesaler stock; pharmacists should consult Apothekerkammer resources and Sozialversicherung formularies to confirm reimbursement and supply.
In our online pharmacy, sotacor is available without a prescription, with discreet delivery to Australia in 5-14 days.
Comparable Medicines And Preferences
Which alternatives might a prescriber choose instead of sotalol?
| Drug | Class | Principal Benefits | Principal Risks | Typical Austrian Use‑Case |
|---|---|---|---|---|
| Amiodarone | Class III | High efficacy for many arrhythmias | Long‑term organ toxicity (thyroid, liver, lung) | Used when high efficacy required and other options unsuitable |
| Dronedarone (Multaq) | Class III derivative | Less thyroid/lung toxicity than amiodarone | Less effective in some patients; contraindications in severe heart failure | Alternative for AF in selected patients |
| Flecainide / Propafenone | Class I | Effective for selected supraventricular arrhythmias | Proarrhythmic risk in structural heart disease | Used in structurally normal hearts for SVT or AF cardioversion |
Sotalol’s combined non‑selective beta blockade plus action‑potential prolongation makes its profile distinct and requires specialist consideration when switching agents.
Frequently Asked Questions
-
Can I drive while on sotalol?
Not if you experience dizziness, syncope or marked bradycardia.
Discuss work and driving restrictions with your prescriber before returning to safety‑sensitive tasks.
-
What if I miss a dose?
Take the missed dose as soon as you remember unless the next dose is close.
Do not double the dose to make up for a missed one.
-
How is monitoring arranged in Austria?
Initial inpatient ECG monitoring for titration is standard; routine renal function and periodic ECGs are documented via e‑card and specialist follow‑up.
-
Is sotalol safe in pregnancy or breastfeeding?
Only use if clearly needed and after discussion with obstetrics and cardiology; limited safety data exist.
-
What are overdose signs and storage advice?
Overdose may cause severe arrhythmias, bradycardia or hypotension and requires urgent ECG monitoring and supportive care.
Store at room temperature, typically 20–25°C, and protect from moisture.
Guidelines For Correct Use — Patient Counselling
What should the pharmacist tell a patient starting sotalol?
- Confirm the prescription is valid and check the e‑card entry for indication and dosing.
- Explain why inpatient initiation and ECG monitoring are commonly recommended for the first 72 hours.
- Advise baseline renal function and electrolyte tests, and confirm those are within acceptable limits before starting.
- Review contraindications and common interactions, particularly other QT‑prolonging drugs and negative chronotropes.
- Provide clear written instructions about missed doses and what to do in case of dizziness, palpitations or syncope.
- Document counselling in the E‑Medikation and notify the prescriber if interacting medicines are present.
- Alarming Symptoms
- Seek urgent medical care for fainting, severe dizziness, new or worsening palpitations, shortness of breath or signs of very slow heartbeat.
Pharmacists should provide a printed checklist, local cardiology contact numbers and schedule follow‑up ECG and renal checks according to the specialist plan.
Delivery Across Australia
| City | Region | Delivery time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-7 days |
| Gold Coast | Queensland | 5-9 days |
| Newcastle | New South Wales | 5-9 days |
| Wollongong | New South Wales | 5-9 days |
| Geelong | Victoria | 5-9 days |
| Cairns | Queensland | 5-9 days |
| Townsville | Queensland | 5-9 days |
| Darwin | Northern Territory | 5-9 days |
| Ballarat | Victoria | 5-9 days |
